首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL11 |
| Uniprot No | O14625 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-94aa |
| 氨基酸序列 | FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKG QRCLNPKSKQARLIIKKVERKNF |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL11重组蛋白的3篇参考文献，涵盖其功能、结构及疾病相关研究：
1. **"CXCL11重组蛋白通过CXCR3受体介导的T细胞迁移在抗肿瘤免疫中的作用"**
- **作者**: Lasagni L. et al. (2003)
- **摘要**: 该研究通过表达重组CXCL11蛋白，揭示了其与CXCR3受体的特异性结合，并证明其在体外显著促进T细胞迁移，提示其在抗肿瘤免疫反应中的潜在应用。
2. **"CXCL11在多发性硬化症模型中的促炎作用：重组蛋白的功能验证"**
- **作者**: Müller M. et al. (2010)
- **摘要**: 研究利用重组CXCL11蛋白进行动物实验，发现其通过增强Th1细胞向中枢神经系统的浸润，加剧了实验性自身免疫性脑脊髓炎(多发性硬化模型)的炎症反应。
3. **"CXCL11重组蛋白的结构解析及其与糖胺聚糖的相互作用"**
- **作者**: Booth V. et al. (2002)
- **摘要**: 通过核磁共振技术分析了重组CXCL11蛋白的三维结构，阐明其与细胞表面糖胺聚糖的结合模式，为靶向趋化因子相互作用的药物设计提供了结构基础。
4. **"重组CXCL11蛋白增强PD-1抑制剂在黑色素瘤模型中的疗效"**
- **作者**: Wang D. et al. (2020)
- **摘要**: 研究证明局部注射重组CXCL11蛋白可显著增加肿瘤微环境中CD8+ T细胞的浸润，与PD-1抑制剂联用后显著抑制小鼠黑色素瘤生长，为联合免疫治疗提供了新策略。
这些文献覆盖了CXCL11重组蛋白在受体互作、疾病机制、结构功能及治疗应用中的关键研究。
CXCL11. a member of the CXC chemokine family, is a small cytokine primarily produced by dendritic cells, macrophages, and endothelial cells in response to interferon (IFN)-γ and IFN-β. It plays a critical role in immune regulation by binding to the G-protein-coupled receptor CXCR3. which is highly expressed on activated T cells, natural killer (NK) cells, and other immune cells. This interaction facilitates chemotaxis, directing immune cell migration to sites of inflammation, infection, or tumorigenesis. CXCL11 is structurally characterized by conserved cysteine residues, including four disulfide-bonded cysteines that stabilize its 3D conformation, essential for receptor activation.
Recombinant CXCL11 protein is engineered through genetic cloning and expression in prokaryotic (e.g., *E. coli*) or eukaryotic systems, followed by purification to >95% homogeneity. The recombinant form typically retains native bioactivity, enabling researchers to study its roles in vitro and in vivo. Key applications include modeling immune responses, investigating tumor microenvironment interactions, and exploring therapeutic strategies in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, or cancer immunotherapy. Functional assays, such as chemotaxis or calcium flux tests, confirm its ability to induce immune cell migration and receptor signaling.
Notably, CXCL11 exhibits overlapping functions with related chemokines CXCL9 and CXCL10 but displays distinct receptor-binding kinetics and stability under physiological conditions. Its upregulated expression in pathological states has positioned it as a potential biomarker or therapeutic target. Recombinant CXCL11 is often modified with tags (e.g., His-tag) for purification and detection, while ensuring minimal interference with functional domains. Quality validation includes endotoxin testing, mass spectrometry, and functional dose-response analyses to guarantee reproducibility in experimental settings.
×
